Spyre Therapeutics CFO Burrows Scott L exercised Options for 7,500 shares at $14.50 per share on 2026-09-01. For investors, the transactions changed his reported holdings to 79,762 shares after sales, while derivative securities stood at 337,357 after the exercise.
Key Highlights
- Burrows Scott L sold 25,732 Spyre Therapeutics shares at prices ranging from $86.25 to $89.35 per share.
- His reported share ownership stood at 79,762 after the sales.
- His derivative securities ownership reached 337,357 after the option exercise.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) CFO Burrows Scott L exercised options for 7,500 shares at $14.50 per share on 1 September 2026.
Option Exercise and Share Sales
The option exercise covered 7,500 shares at $14.50 per share. Burrows Scott L also sold a total of 25,732 Spyre Therapeutics shares in separate transactions conducted between 1 September 2026 and 2 September 2026. The sale prices ranged from $86.25 to $89.35 per share. After those sales, his reported ownership of Spyre Therapeutics common stock was 79,762 shares. The exercise and sales affected separate ownership categories. The records identify Burrows Scott L as Spyre Therapeutics’ chief financial officer.
Reported Holdings After the Transactions
The transactions leave two reported ownership figures for Spyre Therapeutics common stock, reflecting holdings before and after the sales activity. Burrows Scott L’s reported common-stock position was 105,494 shares after the option exercise and 79,762 shares after the sales. His derivative securities position after the exercise was 337,357.
FAQs
Q: What did Spyre Therapeutics CFO Burrows Scott L transact?
A: Burrows Scott L exercised options for 7,500 Spyre Therapeutics shares at $14.50 per share. He also sold 25,732 shares at prices from $86.25 to $89.35.
Q: How many Spyre Therapeutics shares did the CFO own after the sales?
A: Burrows Scott L reported ownership of 79,762 Spyre Therapeutics shares after the sales transactions. His reported position before those sales was 105,494 shares.
Q: How many derivative securities did Burrows Scott L hold?
A: Burrows Scott L reported 337,357 Spyre Therapeutics derivative securities after exercising options. The exercise covered 7,500 shares at $14.50 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.